<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is an <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e> characterized by frequent clotting in arteries and veins and/or <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Autoantibodies to <z:chebi fb="1" ids="16247">phospholipids</z:chebi> and to beta 2 glycoprotein 1 (β(2)GP1) play an important role in the pathogenesis of APS </plain></SENT>
<SENT sid="2" pm="."><plain>Antibodies to the domain 1 of β(2)GP1 (β(2)GP1-D1) have been suggested as a risk marker for <z:mp ids='MP_0005048'>thrombosis</z:mp> and to a lesser extent for <z:e sem="disease" ids="C0032962" disease_type="Disease or Syndrome" abbrv="">pregnancy complications</z:e> in patients suffering from APS </plain></SENT>
<SENT sid="3" pm="."><plain>Despite significant interest in anti-β(2)GP1-D1 antibodies and a considerable research history, the number of studies is still limited and acceptance of the clinical significance of this biomarker is still evolving </plain></SENT>
<SENT sid="4" pm="."><plain>The present review summarizes the current knowledge of anti-β(2)GP1-D1 antibodies and provides insights on recent discoveries </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, we present a suggested guideline for future studies to better understand and verify the clinical utility of anti-β(2)GP1-D1 antibodies </plain></SENT>
</text></document>